Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (tnf-.alpha.) expression
CA 2344616 A1 · Owner: Isis Pharmaceuticals Inc. · Inventors: Bennett, C. Frank; Baker, Brenda F.; Butler, Madeline M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-.alpha. (TNF-.alpha.). Antisense oligonucleotides targeted to nucleic acids encoding TNF-.alpha. are preferred. Methods of using these oligonucleotides for inhibition of TNF-.alpha. expression and for treatment of diseases, particularly inflammatory and autoimmune diseases associated with overexpression of TNF-.alpha. are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 5, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.